Recognition for our commitment to access to healthcare and support for sustainable health systems

AstraZeneca recognised in the 2021 Access to Medicines Index and during the World Economic Forum Davos Agenda


At AstraZeneca, we are working towards a future where all people can access sustainable healthcare solutions for life-changing treatment and prevention. In recognition of the progress being made, AstraZeneca has, once again , been recognised among the top-10 global pharmaceutical companies (7th overall, up from 9th place in 2018) in the Access to Medicine Index (ATMI), a biennial report by the Access to Medicine Foundation evaluating the contributions of 20 pharmaceutical organisations to develop and make certain medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries (LMICs).

The most recent Index results recognise substantial progress in key focus areas, with specific recognition for our work in governance and compliance, where we ranked 3rd in the category, and health systems strengthening – addressing local needs, working with local partners and aiming for sustainability and integration within local health systems.

In addition to a high ranking for governance, the strength and potential of our late-stage pipeline to address public health concerns in LMICs, as well as our structured process for access in R&D, were also acknowledged (6th place).

This performance demonstrates our strategic focus on partnering to build resilient health systems and our work to embed disease awareness education initiatives – a key element of our ambition to meet the needs of diverse patient populations on the journey toward access to healthcare for all.

Strengthening health system resilience

The COVID-19 pandemic has shone a light on the need to strengthen health system resilience, highlighting long-standing vulnerabilities which can only be addressed through collaboration– across industry, governments, healthcare providers, non-governmental organisations and beyond.

In November 2020, AstraZeneca formed an innovative Partnership for Health System Sustainability and Resilience initiative, in collaboration with the World Economic Forum and the London School of Economics (LSE), motivated by a shared commitment to improving population health, through and beyond the pandemic. This was also the subject of CEO Pascal Soriot’s contribution to a session on the first day of the World Economic Forum (WEF)’s Davos Agenda 2021, entitled Building Crisis-Resistant Healthcare Systems in a Post-Covid World.


If we think about healthcare systems in the future and how to be better prepared, the first thing to do is to invest in prevention, early detection and early treatment. We also need a shift in mindset and must consider health as a strategic asset to be invested in - as opposed to a cost to try to minimise.

Pascal Soriot Executive Director and CEO

On 25 January 2021, AstraZeneca was also recognised by Corporate Knights as one of the world’s 100 Most Sustainable Corporations out of more than 8,000 companies with more than US$1 billion in revenues, ranking 82nd overall and fourth in pharmaceuticals.

For more information

Access to Medicine Index:


100 Most Sustainable Corporations:



  • Sustainability